Anti-Dickkopf-1 Antibody, Non-Fucosylated (BioBet-771ZP) (CAT#: BioBet-771ZP) Datasheet

DKK1

dickkopf WNT signaling pathway inhibitor 1

This gene encodes a protein that is a member of the dickkopf family. It is a secreted protein with two cysteine rich regions and is involved in embryonic development through its inhibition of the WNT signaling pathway. Elevated levels of DKK1 in bone marrow plasma and peripheral blood is associated with the presence of osteolytic bone lesions in patients with multiple myeloma.

DKK1; dickkopf WNT signaling pathway inhibitor 1; SK; DKK-1; dickkopf-related protein 1; hDkk-1; dickkopf-1 like; dickkopf 1 homolog; dickkopf-like protein 1; dickkopf related protein-1

Extracellular region or secreted

Diseases associated with DKK1 include Chiari Malformation Type I and Osteoporosis, Juvenile.

Its related pathways are Regulation of Wnt-mediated beta catenin signaling and target gene transcription and Signaling by GPCR.

By inhibiting the interaction between LRP5/6 and Wnt and forming a ternary complex with the transmembrane protein KREMEN to promote the internalization of LRP5/6 to antagonize the typical Wnt signal. DKKs play an important role in the development of vertebrates. They locally inhibit Wnt-regulated processes, such as front and back axial patterns, limb development, somatic cell formation and eye formation. In adults, Dkks is associated with bone formation and bone disease, cancer, and Alzheimer's disease. Inhibits the pro-apoptotic function of KREMEN1 in a wnt-independent manner and has anti-apoptotic activity (similar).

Cell Biology and Cellular Response antibody; Developmental Biology antibody; Immune System antibody; Signaling Transduction antibody

1.Glycosylation at Ser61, Thr155, Ser163, Thr164, Ser169, Thr172, Thr173, Thr181, and Asn256 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

BioBet-771ZP

Human

Human

BHQ880 is a human neutralizing IgG1 anti-DKK1 monoclonal antibody, that is being investigated for its impact on multiple myeloma-related bone disease and as an agent with potential anti-myeloma activity. BHQ880 in combination with zoledronic acid and anti-myeloma therapy was well tolerated and demonstrated potential clinical activity in patients with relapsed or refractory multiple myeloma.

Bone-related Diseases; Multiple Myeloma

Bone-related Diseases; Multiple Myeloma